Catalysts for collaboration and cure

Article

The investigative research group Catalyst for a Cure has made significant discoveries developing a better understanding of the insidious changes caused by glaucoma and is developing strategies to prevent them.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A sign outside the US Food and Drug Administration headquarters. Image credit: ©Tada Images – stock.adobe.com

US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism

Jordana Joy
January 14th 2025
Article

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Martin David Harp
January 13th 2025
Article

The launch follows a CE Mark received in late 2024

A Snellen chart and OCT image scans on a table, with glasses next to them. Image credit: ©izzuan – stock.adobe.com

Study explores possible applications of retinal imaging in schizophrenia detection

Jordana Joy
January 13th 2025
Article

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases

A mother who has recently given birth looks at her baby, who rests in an incubator. Image credit: ©Richard Semik – stock.adobe.com

Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics

Lynda Charters
January 10th 2025
Article

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

A gloved hand, holding a syringe, is pictured next to a US FDA (Food and Drug Administration) logo. Image credit: ©ra2 studio – stock.adobe.com

ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901

Hattie Hayes
January 9th 2025
Article

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

© 2025 MJH Life Sciences

All rights reserved.